Ondansetron Bluefish Pharmaceuticals (Ondansetron)

Ondansetron works by selectively blocking serotonin (5‑HT3) receptors in the brain’s chemoreceptor trigger zone and in the gastrointestinal tract. This inhibition stops the serotonin‑driven signaling that normally triggers the vomiting reflex, thereby reducing the sensation of nausea.

The dose of ondansetron is determined by the prescribing clinician based on the specific indication, patient weight, renal function and other clinical factors. Patients should follow the exact dosage instructions provided by their healthcare professional.

Safety data for ondansetron in pregnancy are limited, and it should be used only if the potential benefit justifies any possible risk to the fetus. While limited information exists for lactation, the decision to continue therapy while breastfeeding should be made in consultation with a physician.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Ondansetron belongs to the 5‑HT3 receptor antagonist class, which is generally more effective for acute chemotherapy‑induced nausea than older agents such as metoclopramide or antihistamines. Its side‑effect profile is favorable, though it requires attention to cardiac safety, especially when combined with other QT‑prolonging drugs.

Store the product at temperatures below 25 °C, in its original container, protected from moisture and direct sunlight. Do not refrigerate or freeze the tablets, and keep them out of reach of children.

The medication is taken orally, usually as a tablet, with or without water. It can be administered with or without food, but patients should follow the specific instructions given by their prescriber regarding timing relative to chemotherapy or surgery.

The most serious risks include QT‑interval prolongation that may lead to cardiac arrhythmias, severe allergic reactions such as anaphylaxis, and, rarely, serotonin syndrome when combined with other serotonergic drugs. Patients should seek immediate medical attention if they experience palpitations, rash, or severe dizziness.

Ondansetron should be avoided in patients with known hypersensitivity to the drug or any of its components, and in those with a history of congenital long QT syndrome or uncontrolled electrolyte abnormalities. Caution is also advised for individuals taking other medications that significantly prolong the QT interval.